These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

639 related items for PubMed ID: 15763607

  • 1. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS.
    Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib.
    Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston H, Litschig S, Sloan VS.
    Curr Med Res Opin; 2005 Apr; 21(4):517-26. PubMed ID: 15899100
    [Abstract] [Full Text] [Related]

  • 3. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib.
    Fleischmann R, Sheldon E, Maldonado-Cocco J, Dutta D, Yu S, Sloan VS.
    Clin Rheumatol; 2006 Feb; 25(1):42-53. PubMed ID: 16132165
    [Abstract] [Full Text] [Related]

  • 4. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
    Tannenbaum H, Berenbaum F, Reginster JY, Zacher J, Robinson J, Poor G, Bliddal H, Uebelhart D, Adami S, Navarro F, Lee A, Moore A, Gimona A.
    Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
    [Abstract] [Full Text] [Related]

  • 5. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215].
    Wittenberg RH, Schell E, Krehan G, Maeumbaed R, Runge H, Schlüter P, Fashola TO, Thurston HJ, Burger KJ, Trechsel U.
    Arthritis Res Ther; 2006 Nov; 8(2):R35. PubMed ID: 16469112
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM.
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
    Dougados M, Moore A, Yu S, Gitton X.
    Arthritis Res Ther; 2007 Mar; 9(1):R11. PubMed ID: 17266764
    [Abstract] [Full Text] [Related]

  • 8. Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority study.
    Emery P, Koncz T, Pan S, Lowry S.
    Clin Ther; 2008 Jan; 30(1):70-83. PubMed ID: 18343244
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand.
    Grifka JK, Zacher J, Brown JP, Seriolo B, Lee A, Moore A, Gimona A.
    Clin Exp Rheumatol; 2004 Jan; 22(5):589-96. PubMed ID: 15485012
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SK, Senftleber I, Gitton X, Moore A, Sloan VS, Poór G.
    Arthritis Rheum; 2004 Aug 15; 51(4):549-57. PubMed ID: 15334426
    [Abstract] [Full Text] [Related]

  • 11. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
    Hawkey CC, Svoboda P, Fiedorowicz-Fabrycy IF, Nasonov EL, Pikhlak EG, Cousin M, Gitton X, Hoexter G.
    J Rheumatol; 2004 Sep 15; 31(9):1804-10. PubMed ID: 15338504
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
    Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ, Vioxx, Acetaminophen, Celecoxib Trial (VACT) Group.
    JAMA; 2002 Jan 02; 287(1):64-71. PubMed ID: 11754710
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults.
    Kivitz A, Fairfax M, Sheldon EA, Xiang Q, Jones BA, Gammaitoni AR, Gould EM.
    Clin Ther; 2008 Dec 02; 30(12):2366-77. PubMed ID: 19167595
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of lumiracoxib in osteoarthritis: a review of nine studies.
    Berenbaum F, Grifka J, Brown JP, Zacher J, Moore A, Krammer G, Dutta D, Sloan VS.
    J Int Med Res; 2005 Dec 02; 33(1):21-41. PubMed ID: 15651713
    [Abstract] [Full Text] [Related]

  • 15. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
    Fleischmann R, Tannenbaum H, Patel NP, Notter M, Sallstig P, Reginster JY.
    BMC Musculoskelet Disord; 2008 Mar 07; 9():32. PubMed ID: 18328090
    [Abstract] [Full Text] [Related]

  • 16. Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis.
    Bingham CO, Bird SR, Smugar SS, Xu X, Tershakovec AM.
    Osteoarthritis Cartilage; 2008 Nov 07; 16(11):1289-93. PubMed ID: 18514551
    [Abstract] [Full Text] [Related]

  • 17. Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo.
    Bingham CO, Smugar SS, Wang H, Peloso PM, Gammaitoni A.
    Pain Med; 2011 Mar 07; 12(3):352-61. PubMed ID: 21332932
    [Abstract] [Full Text] [Related]

  • 18. A prospective, randomized, double-blind, multicenter comparative study on the safety and efficacy of Celecoxib and GCSB-5, dried extracts of six herbs, for the treatment of osteoarthritis of knee joint.
    Park YG, Ha CW, Han CD, Bin SI, Kim HC, Jung YB, Lim HC.
    J Ethnopharmacol; 2013 Oct 07; 149(3):816-24. PubMed ID: 23954277
    [Abstract] [Full Text] [Related]

  • 19. Lumiracoxib 400 mg compared with celecoxib 400 mg and placebo for treating pain following dental surgery: a randomized, controlled trial.
    Fricke J, Davis N, Yu V, Krammer G.
    J Pain; 2008 Jan 07; 9(1):20-7. PubMed ID: 17933588
    [Abstract] [Full Text] [Related]

  • 20. A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis.
    Schnitzer TJ, Dattani ID, Seriolo B, Schneider H, Moore A, Tseng L, Sallstig P, Rebuli R, Maxwell T.
    Clin Rheumatol; 2011 Nov 07; 30(11):1433-46. PubMed ID: 21607551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.